Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-03-31false222024-04-01truefalsefalseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 05068289 2024-04-01 2025-03-31 05068289 2023-04-01 2024-03-31 05068289 2025-03-31 05068289 2024-03-31 05068289 c:Director1 2024-04-01 2025-03-31 05068289 d:CurrentFinancialInstruments 2025-03-31 05068289 d:CurrentFinancialInstruments 2024-03-31 05068289 d:CurrentFinancialInstruments 2 2025-03-31 05068289 d:CurrentFinancialInstruments 2 2024-03-31 05068289 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 05068289 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 05068289 d:ShareCapital 2025-03-31 05068289 d:ShareCapital 2024-03-31 05068289 d:RetainedEarningsAccumulatedLosses 2025-03-31 05068289 d:RetainedEarningsAccumulatedLosses 2024-03-31 05068289 c:FRS102 2024-04-01 2025-03-31 05068289 c:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 05068289 c:FullAccounts 2024-04-01 2025-03-31 05068289 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 05068289 6 2024-04-01 2025-03-31 05068289 f:PoundSterling 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure

Registered number: 05068289










BDS PHARMACY (UK) LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2025


 
BDS PHARMACY (UK) LIMITED
REGISTERED NUMBER: 05068289

STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2025

2025
2024
Note
£
£

Fixed assets
  

Investments
  
100
100

  
100
100

Current assets
  

Debtors
  
890,000
1,022,928

Cash at bank and in hand
  
429,430
1,076

  
1,319,430
1,024,004

Creditors: amounts falling due within one year
 6 
(37,401)
(25,041)

Net current assets
  
 
 
1,282,029
 
 
998,963

Total assets less current liabilities
  
1,282,129
999,063

Net assets
  
1,282,129
999,063


Capital and reserves
  

Called up share capital 
  
7,230
7,230

Profit and loss account
  
1,274,899
991,833

  
1,282,129
999,063


Page 1

 
BDS PHARMACY (UK) LIMITED
REGISTERED NUMBER: 05068289
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



Mr A S Sodhi
Director

Date: 4 November 2025

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
BDS PHARMACY (UK) LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1.


General information

BDS Pharmacy (UK) Limited is a private company, limited by share capital, incorporated in England and Wales under registration number: 05068289. The address of the registered office is Level 5A, Maple House, 149 Tottenham Court Road, London W1T 7NF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Valuation of investments

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Income statement for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2024 - 2).

Page 3

 
BDS PHARMACY (UK) LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

4.


Fixed asset investments





Investments in subsidiary company

£



Cost or valuation


At 1 April 2024
100



At 31 March 2025
100





5.


Debtors

2025
2024
£
£


Amounts owed by subsidiary company (refer to note 8)
-
132,927

Amounts owed by associated company (refer to note 8)
890,000
890,000

890,000
1,022,927



6.


Creditors: Amounts falling due within one year

2025
2024
£
£

Corporation tax
41
41

Directors' loan account
36,460
25,000

Accruals and deferred income
900
-

37,401
25,041



7.


Controlling party

The company was under the control of the director Mr A S Sodhi (59% share) and Mrs H K Sodhi (41% share), by virtue of the fact that between them they own 100% of the issued share capital.


 
Page 4